Vistagen Therapeutics (VTGN) Accumulated Expenses (2011 - 2026)
Vistagen Therapeutics (VTGN) posted Accumulated Expenses of $8.8 million for Q1 2026, down 5.39% sequentially from $9.3 million in Q4 2025, and down 0.62% YoY from $8.8 million in Q1 2025.
Vistagen Therapeutics (VTGN) Accumulated Expenses (2011 - 2026) Analysis & Trends
Vistagen Therapeutics has reported Accumulated Expenses for 14 years, with the latest figure at $8.8 million in Q1 2026.
- Quarterly Accumulated Expenses fell 0.62% year-over-year to $8.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.8 million (down 0.62% YoY) and the FY2026 annual result came in at $8.8 million, down 0.62% from the prior year.
- Accumulated Expenses fell to $8.8 million in Q1 2026 per VTGN's latest filing, from $9.3 million in the prior quarter.
- Over five years, Accumulated Expenses peaked at $9.3 million in Q4 2025 and troughed at $35000.0 in Q2 2023.
- A 5-year average of $3.6 million and a median of $2.2 million in 2024 frame the typical range for Accumulated Expenses.
- The sharpest annual moves came in 2022 and 2024: Accumulated Expenses sank 88.8% in 2022, then jumped 6082.86% in 2024.
- Over 5 years, Accumulated Expenses stood at $1.1 million in 2022, then plunged by 88.09% to $129300.0 in 2023, then soared by 4129.7% to $5.5 million in 2024, then jumped by 69.21% to $9.3 million in 2025, then fell by 5.39% to $8.8 million in 2026.
- According to Business Quant data, Accumulated Expenses over the past three periods registered $8.8 million, $9.3 million, and $8.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Vistagen Therapeutics | 10.49 Mn | 10.49 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8.76 Mn |
| Dec 31, 2025 | 9.25 Mn |
| Sep 30, 2025 | 8.42 Mn |
| Jun 30, 2025 | 6.58 Mn |
| Mar 31, 2025 | 8.81 Mn |
| Dec 31, 2024 | 5.47 Mn |
| Sep 30, 2024 | 3.82 Mn |
| Jun 30, 2024 | 2.16 Mn |
| Mar 31, 2024 | 2.24 Mn |
| Dec 31, 2023 | 129,300.00 |
| Sep 30, 2023 | 292,600.00 |
| Jun 30, 2023 | 35,000.00 |
| Mar 31, 2023 | 796,000.00 |
| Dec 31, 2022 | 1.09 Mn |
| Sep 30, 2022 | 1.19 Mn |
| Jun 30, 2022 | 240,700.00 |
| Mar 31, 2022 | 1.33 Mn |
| Dec 31, 2021 | 2.63 Mn |
| Sep 30, 2021 | 1.99 Mn |
| Jun 30, 2021 | 2.15 Mn |